Generic Fycompa Availability

Last updated on Jun 11, 2025.

Fycompa is a brand name of perampanel, approved by the FDA in the following formulation(s):

FYCOMPA (perampanel - suspension;oral)

• Manufacturer: CATALYST PHARMS
  Approval date: April 29, 2016
  Strength(s): 0.5MG/ML ^[RLD]

FYCOMPA (perampanel - tablet;oral)

• Manufacturer: CATALYST PHARMS
  Approval date: October 22, 2012
  Strength(s): 2MG ^{[RLD] [AB]}, 4MG ^{[RLD] [AB]}, 6MG ^{[RLD] [AB]}, 8MG ^{[RLD] [AB]}, 10MG ^{[RLD] [AB]}, 12MG ^{[RLD] [AB]}

Is there a generic version of Fycompa available?

A generic version of Fycompa has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Fycompa and have been approved by the FDA:

perampanel tablet;oral

• Manufacturer: TEVA PHARMS USA INC
  Approval date: May 23, 2025
  Strength(s): 2MG ^[AB], 4MG ^[AB], 6MG ^[AB], 8MG ^[AB], 10MG ^[AB], 12MG ^[AB]

Note: No generic formulation of the following product is available.

• perampanel - suspension;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fycompa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
  Patent 6,949,571
  Issued: September 27, 2005
  Inventor(s): Nagato; Satoshi et al.
  Assignee(s): Eisai Co., Ltd. (Tokyo, JP)
  

  The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. ##STR1##
  In the formula, Q indicates NH, O or S; and R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C.sub.1-6 alkyl group or a group represented by the formula --X-A (wherein X indicates a single bond, an optionally substituted C.sub.1-6 alkylene group etc.; and A indicates an optionally substituted C.sub.6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).

  Patent expiration dates:

  • May 23, 2025
    
    ✓ 
    Patent use: TREATMENT OF EPILEPSY
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • May 23, 2025
    
    ✓ 
    Patent use: TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • May 23, 2025
    
    ✓ 
    Patent use: TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • May 23, 2025
    
    ✓ 
    Patent use: TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • May 23, 2025
    
    ✓ 
    Patent use: TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Method for producing 1, 2-dihydropyridine-2-one compound
  Patent 8,772,497
  Issued: July 8, 2014
  Inventor(s): Arimoto Itaru & Nagato Satoshi & Sugaya Yukiko & Urawa Yoshio & Ito Koichi & Naka Hiroyuki & Omae Takao & Kayano Akio & Nishiura Katsutoshi
  Assignee(s): Eisai R&D Management Co., Ltd.
  

  The present inventions provide a method for commercially producing a 1,2-dihydropyridine-2-one compound represented by the following formula (III-a)

  Patent expiration dates:

  • July 1, 2026
    
    ✓ 
    Drug substance

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer